Zydus Cadila on Thursday said it has got final approval from the US health regulator to market Mesalamine suppositories.
The drug is used to treat ulcerative proctitis, a type of bowel disease.
"Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use...1000 mg," the drug firm said in a regulatory filing.
Mesalamine Suppositories is an aminosalicylate anti-inflammatory drug and is believed to work by blocking the production of certain natural chemicals that may cause pain and swelling.
This will be manufactured at the group's topical manufacturing facility at Ahmedabad.
The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading down 0.10 per cent at Rs 1,468.95 per scrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app